Press Releases

October 12, 2020
Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates
- Newly disclosed data build on topline results and continue to support GB004’s differentiated approach of targeting epithelial barrier restoration in patients with ulcerative colitis - - GB004 demonstrated superior barrier protection compared to tofacitinib in pre-clinical human monolayer assay -
Additional Formats
September 10, 2020
Gossamer Bio Announces Participation in Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2020-- Gossamer Bio, Inc.   (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its
Additional Formats
June 1, 2020
Gossamer Bio Announces Participation in Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Jun. 1, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its participation
Additional Formats
May 29, 2020
Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific Program
SAN DIEGO --(BUSINESS WIRE)--May 29, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of
Additional Formats
Displaying 1 - 10 of 17